Research Direction 1: Targeted Radiopharmaceutical
Focusing on the clinical demands of imaging and therapy, this direction aims to design and construct tumor-specific multivalent ligands, including small molecules, peptides, and nucleic acid aptamers, and to develop novel chelators that enable mild-condition direct labeling or bifunctional chelation of radionuclides such as Ga-68, Lu-177, Ac-225, and Ra-223. These advances will improve labeling efficiency and in vivo stability of radiopharmaceuticals. On this basis, systematic preclinical and clinical studies of targeted radiotheranostic drugs will be carried out, including physicochemical property evaluation, biodistribution profiling, pharmacokinetics, and pharmacodynamics, as well as real-time monitoring of in vivo drug distribution and efficacy, thereby accelerating the clinical translation of targeted radiopharmaceuticals.

Research Direction 2: Multi-Specific Nucleic Acid Aptamer
This direction focuses on developing efficient construction strategies for multi-specific nucleic acid aptamers. By leveraging the overexpression of multiple target proteins on tumor cell membranes, these aptamers can achieve cooperative multi-target recognition, significantly enhancing precision and specificity of molecular recognition, and generating novel molecular tools. Building on this foundation, new targeted drug delivery systems based on multi-specific aptamers will be established, along with efficient degradation technologies for cell membrane proteins, and innovative methods for early detection and precision diagnosis of major diseases such as cancer. This direction will advance the application of aptamers in theranostics and broaden their role in precision medicine research.

Research Direction 3: Novel Chemiluminescent Probes and Precision Imagin
This direction aims to design and synthesize chemiluminescent probes with entirely new molecular scaffolds. Through structural optimization, the emission wavelength, quantum yield, and other optical properties of these probes will be precisely regulated. By introducing functional groups with specific reactivity, probe systems capable of responding selectively to biomolecules such as enzymes, peroxynitrite (ONOO⁻), and hydrogen peroxide (H₂O₂) will be developed, enabling real-time and noninvasive imaging of key molecules in vivo. Leveraging these novel chemiluminescent probes, research will be conducted on early disease diagnosis, promoting their application in biomedical imaging and translational medicine, and ultimately providing advanced imaging tools and technical support for early detection and precision treatment of diseases.